GI Path & AP Research Director, Professor @EmoryPathology. Chair @Pathologists Surg Path Cmte. Reviews Editor @Histo_Journal. Education Chair @usgips.
Nov 7, 2022 • 80 tweets • 36 min read
01/ Buckle up, everyone, it’s time for a Tweetorial. Been working on this one for a while. This time, I’ll focus on the most common mesenchymal malignancy of the digestive tract: gastrointestinal stromal tumor (GIST). #pathology#gipath#PathTwitter02/ GIST arises from the interstitial cells of Cajal. It can originate anywhere in the GI tract, though most cases occur in the stomach or small bowel. Rectum cases are uncommon, and GIST is very rare in the esophagus, colon, or appendix.
Apr 21, 2021 • 64 tweets • 25 min read
1/ Hello again, everyone. I have finally put together my third Tweetorial, and I will be focusing it on one single entity, the enigmatic and often frustrating Low-Grade Appendiceal Mucinous Neoplasm (LAMN). #pathology#GIpath2/ For starters, what is a LAMN? The name gets you most of the way there. It technically is an appendiceal adenocarcinoma, because it is an epithelial malignancy composed of glandular epithelium.
Mar 11, 2020 • 55 tweets • 26 min read
1/ In Dec. 2018, I posted my first #Tweetorial, on digestive tract neuroendocrine neoplasms. I polled Twitter asking what my next topic would be, and the winner was hepatic masses. More than a YEAR later, here it is! #pathology#liverpath2/ Broad points: Most liver masses are benign, especially in younger patients. Older and cirrhotic patients are at increased risk for malignancy. Masses in cirrhosis are almost always primary liver malignancies (usually HCC).